To investigate this hypothesis, we utilized 2 survival analysis databases for BC—KMplot (40) and BreastMark (41)—and assessed the relationship between C1q expression and overall survival (OS) outcomes for patients with HER2+, Luminal A, Luminal B, and Basal (triple-negative BC [TNBC]) subtypes. Here, ERBB2 is linked to breast cancer.